SEC Form 4 · accession 0001628280-26-057166
BECTON DICKINSON & CO · BDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas E Polen Jr.
Officer — Chairman, CEO and President · Director
Period of report
Aug 13, 2026
Accepted (ET)
Aug 14, 2026 · 4:36 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000010795
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 13, 2026 | M | 43,278 | $167.25 | A | 153,441 | D | |
| Common Stock | Aug 13, 2026 | D | 39,126 | $185.00 | D | 114,315 | D | |
| Common Stock | Aug 13, 2026 | S | 4,152 | $185.00 | D | 110,163 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Appreciation RightsF1,F2 | $167.25 | Aug 13, 2026 | M | 43,278 | D | Nov 26, 2018 | Nov 26, 2027 | Common Stock | 43,278 | 0 | D |
Explanation of responses
- F1Award terms reflect the adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.
- F2The stock appreciation rights vested in four annual installments beginning November 26, 2018.
Remarks
The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026.